On August 26, Argenx SE rose 3.06% in regular trading, reaching $1,050.73 per share with turnover of $150 million. The move represents a recovery bounce following the prior session's pullback, driven by continued positive sentiment around its myositis clinical data.

The company's core product Vyvgart Hytrulo achieved the primary endpoint in its phase 3 ALKIVIA trial evaluating autoimmune myositis, showing a statistically significant 15.4-point improvement in mean Total Improvement Score versus placebo at week 52. In the IMNM subgroup, treated patients demonstrated a 14.8-point greater improvement with a p-value of 0.0048. This marks the first phase 3 trial to show significant improvement in immune-mediated necrotizing myopathy, a disease with no approved therapies.

Multiple institutions issued positive assessments. Wedbush raised its target price to $1,150 and maintained an Outperform rating. RBC, Morgan Stanley, and Oppenheimer all noted the data reduces uncertainty around Vyvgart's estimated $1.5 to $2 billion myositis market opportunity. The company's Q2 revenue of $1.542 billion beat consensus by 7%, while EPS of $7.32 exceeded estimates by 17%, underscoring strong fundamental momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)